Skip to Content

Kahn

Steven E. Kahn, M.B., Ch.B.

Metabolism, Endocrinology and Nutrition

Professor of Medicine


Focus

Assessment of islet function and insulin action in states of normal and abnormal carbohydrate metabolism. Determination of defects in islet function and their relationship to genetic markers in subjects at high risk for developing type 2 diabetes. Evaluations of the mechanisms regulating the synthesis and secretion of islet amyloid polypeptide by the pancreatic ß-cell in vitro and in vivo, and its deposition as islet amyloid. Role of fat distribution on metabolic variables associated with diabetes and cardiovascular disease.


Publications

Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Berman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr:  Quantification of the relationship between insulin sensitivity andß-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993.

Verchere CB, D’Alessio, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE:   Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide.  Proc Natl Acad Sci USA 93:3492-3496, 1996.

Cnop M, Landchild M, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH, and Kahn SE:  The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations:  Distinct metabolic effects of two fat compartments.  Diabetes 51:1005-1015, 2002.

Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE and  American Diabetes Association GENNID Study Group:  ß-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S.  Diabetes 51:2170-2178, 2002.

Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE:  Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins:  Evidence for independent roles of age and sex.  Diabetologia 46:459-469, 2003.

Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Cnop M, Prigeon RL, Kahn SE:  Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid.  Diabetes 52:372-379, 2003.

Kahn SE:  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes.  Diabetologia 46:3-19, 2003.

Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH and Kahn SE:  Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome.  Diabetes 53:2087-2094, 2004.

Hull RL, Westermark GT, Westermark P and Kahn SE:  Islet amyloid:  a critical entity in the pathogenesis of type 2 diabetes.  J Clin Endocrinol Metab 89:3629-3643, 2004.

Hull RL, Kodama K, Utzschneider KM, Carr DB, Prigeon RL and Kahn SE:  Dietary fat-induced obesity in mice results in beta cell hyperplasia but not increased insulin release:  evidence for specificity of impaired beta cell adaptation.  Diabetologia 48:1350-1358, 2005.

Hull RL, Shen ZP, Watts MR, Kodama K, Carr DB, Utzschneider KM, Zraika S, Wang F and Kahn SE:  Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide.  Diabetes 54:2235-2244, 2005.

Kahn SE, Hull RL, Utzschneider KM:  Mechanisms linking obesity to insulin resistance and type 2 diabetes.  Nature 444:840-6, 2006.

van Genugten RE, Utzschneider KM, Tong J, Gerchman F, Zraika S, Udayasankar J, Boyko EJ, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group:  Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes.  Diabetes 55:3529-35, 2006.

Zraika S, Hull RL, Udayasankar J, Clark A, Utzschneider KM, Tong J, Gerchman F, Kahn SE:  Identification of the amyloid-degrading enzyme neprilysin in mouse islets and potential role in islet amyloidogenesis.  Diabetes 56:304-10, 2007.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G, ADOPT Study Group:  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.  N Engl J Med 355:2427-43, 2006.

Kahn SE, Zinman B:  Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes.  Diabetes Care 30:1672-1676, 2007.

Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, Scherer PE, Boyko EJ, Fujimoto WY, Kahn SE:  Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes.  Diabetes Care 30:677-682, 2007.

Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, Knowler WC, Nathan DM, Altshuler D:  Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program.  Diabetes 56:531-536, 2007.

Zraika S, Hull RL, Udayasankar J, Clark A, Utzschneider KM, Tong J, Gerchman F, Kahn SE:  Identification of the amyloid-degrading enzyme neprilysin in mouse islets and potential role in islet amyloidogenesis.  Diabetes 56:304-310, 2007.